|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.07.26 - 12:03
|
Legend Biotech Announces CEO Transition (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition....
|
|
|
16.07.26 - 04:15
|
GENSCRIPT BIO : Legend's CARVYKTI 2Q25 Trade Sales Approx. USD657 million (AAStocks)
|
|
|
GENSCRIPT BIO (01548.HK) announced that CARVYKTI(R) generated net trade sales of approximately USD657 million for the quarter ended June 30, 2025 under the collaboration and license agreement entered into on December 21, 2017 between associate company Legend Biotech Corporation (LEGN.US) and Janssen Biotech.AASTOCKS Financial Ne......
|
|
|
|
|
|
|
|
|
|
|
18.06.26 - 03:24
|
Legend Biotech Corporation Announces Pricing of Public Offering (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters' option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to ...
|
|
|
|
|
|
|
17.06.26 - 22:33
|
Legend Biotech Corporation Announces Proposed Public Offering (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company. All of the ADSs will be offered by Legend Biotech. Legend Biotech also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering....
|
|
|
|
|
|
|
|
|
02.06.26 - 15:33
|
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
